Abramson Cancer Center
🇺🇸United States
Safe and Explainable AI
Not yet recruiting
- Conditions
- Artifical InteligenceCardiologyBreast CancerSepsis
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 300000
- Registration Number
- NCT06694181
Prostate Tissue BioBank
Recruiting
- Conditions
- Prostate CancerGenetic Predisposition
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT06659614
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Integrating Telehealth to Advance Lung Cancer Screening
Not Applicable
Recruiting
- Conditions
- Early Detection of CancerTelemedicineDecision Making
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 6000
- Registration Number
- NCT06638554
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Community Support Program for Lung Cancer Screening Volume II
Not Applicable
Recruiting
- Conditions
- Lung Cancer
- Interventions
- Behavioral: TransportationBehavioral: Scheduling
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 100
- Registration Number
- NCT06628167
- Locations
- 🇺🇸
Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Early Phase 1
Recruiting
- Conditions
- GlioblastomaRecurrent GlioblastomaGlioblastoma Multiforme of Brain
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT06613841
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
BHB & CAR-T for Lymphomas
Not Applicable
Recruiting
- Conditions
- Large B-cell Lymphoma
- Interventions
- Dietary Supplement: R-1,3-Butanediol
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT06610344
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vaccine Responses in Cancer
Recruiting
- Conditions
- Viral Vaccines
- Interventions
- Biological: Influenza vaccinationBiological: Zoster Vaccine Recombinant
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-09-20
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 250
- Registration Number
- NCT06605625
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Hypofractionated WPPT With HDR Boost
Phase 2
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Radiation: Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT06591819
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
Not Applicable
Completed
- Conditions
- Breast CancerProstate Cancer
- Interventions
- Behavioral: Cognitive Behavioral therapy for insomnia (CBT-I)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT06604247
- Locations
- 🇺🇸
University Of Pennsylvania, Behavioral Sleep Medicine Program, Philadelphia, Pennsylvania, United States
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Phase 1
Recruiting
- Conditions
- Urothelial Carcinoma BladderBladder Cancer
- Interventions
- Radiation: Concurrent Immunotherapy and Radiation Therapy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT06586255
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath